Figure 2
Kaplan–Meier estimates of overall survival in 88 Mayo Clinic patients with low- or intermediate-1-risk PMF, according to the DIPSS-plus,10 stratified by the presence or absence of CALR and ASXL1 mutations.
Figure 2 | Leukemia
Kaplan–Meier estimates of overall survival in 88 Mayo Clinic patients with low- or intermediate-1-risk PMF, according to the DIPSS-plus,10 stratified by the presence or absence of CALR and ASXL1 mutations.
